Valeant raises analysts' concerns with new EPS reporting
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals' 2008 results drew questions about its financial reporting after it excluded certain expenses from its cash earnings per share (EPS) accounting.